Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | ADH5 | P11766 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764228 | 0.89 | PDK4 (0.52) | WDR5PDK4RORCGRM5GRM1 | |
| SCHEMBL34465791 | 0.85 | NR1H2 (0.47) | WDR5PDK4ELANEGRM5GRM1 | |
| SCHEMBL1764101 | 0.83 | ELANE (0.51) | WDR5PDK4ELANE | |
| SCHEMBL31701876 | 0.80 | PDK4 (0.49) | WDR5PDK4GRM5GRM1NAMPT | |
| SCHEMBL1763861 | 0.79 | PDK4 (0.50) | WDR5PDK4GRM5GRM1NAMPT | |
| SCHEMBL27007919 | 0.78 | SOS1 (0.42) | WDR5PDK4ELANEGRM5GRM1 | |
| SCHEMBL30745989 | 0.78 | SOS1 (0.42) | WDR5PDK4ELANEGRM5GRM1 | |
| SCHEMBL27007900 | 0.77 | SOS1 (0.40) | WDR5PDK4ELANEGRM5GRM1 | |
| SCHEMBL15011298 | 0.76 | ELANE (0.43) | WDR5PDK4RORCELANEGRM5 | |
| SCHEMBL29813115 | 0.76 | GRM1 (0.54) | WDR5PDK4GRM5GRM1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2321274-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | WDR5 4243/4885PDK4 717/4885RORC 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.